Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2012
10/18/2012CA2831388A1 Asymmetrically substituted anthrapyridazone derivatives as cytostatics
10/18/2012CA2831341A1 Nutritional compositions including branched chain fatty acids for wound healing
10/18/2012CA2830970A1 Nutritional compositions including branched chain fatty acids and methods of using same
10/18/2012CA2830896A1 Aqueous ophthalmic composition
10/18/2012CA2830689A1 1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment
10/18/2012CA2830204A1 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
10/18/2012CA2829676A1 Cycloalkenyl aryl derivatives for cetp inhibitor
10/18/2012CA2827875A1 Use of n-(4-methoxyphenyl)-1-phenyl-1h-pyrazol-3-amine and related compounds
10/18/2012CA2827739A1 Prostate cancer therapy with hsp90 inhibitory compounds
10/18/2012CA2826188A1 Aclidinium for use in improving the quality of sleep in respiratory patients
10/17/2012EP2511283A1 N6-substituted adenosine derivatives, n6-substituted adenine derivatives and uses thereof
10/17/2012EP2511282A1 Uracyl Spirooxetane Nucleosides
10/17/2012EP2511281A1 Acyclic nucleoside phosphonate derivatives and medicine uses thereof
10/17/2012EP2511276A1 Pyrrolo[2,3-d]pyrimidine derivative
10/17/2012EP2511275A1 Novel piperidinyl monocarboxylic acids as S1P1 receptor agonists
10/17/2012EP2511273A1 Inhibitors of viral replication, their process of preparation and their therapeutical uses
10/17/2012EP2511272A1 Synthetic analogues of abscisic acid with anti-inflammatory and insulin release stimulation effects on human cells
10/17/2012EP2511271A1 Heteroarylcarboxylic acid ester derivative
10/17/2012EP2511269A1 Fused heterocyclic compound having amino group
10/17/2012EP2511268A1 Oxazine derivative
10/17/2012EP2511267A1 3-((n-acylated aminoacyl)amino)pyrazoles as inhibitors of beta-amyloid peptide production useful for the treatment of alzheimer's disease
10/17/2012EP2511266A1 Luminescent 1-Hydroxy-2-Pyridinone Chelates of Lanthanides
10/17/2012EP2511265A1 Benzamide compound
10/17/2012EP2511264A1 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
10/17/2012EP2511263A1 Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases
10/17/2012EP2511262A1 Process for producing 2-amino-2-[2-[4-(3-benzyloxy-phenylthio)-2-chlorophenyl[ethyl]-1,3-propanediol hydrochloride
10/17/2012EP2511260A1 Aromatic compound, modification carrier that uses same and is used for synthesizing an oligonucleotide derivative, oligonucleotide derivative, and oligonucleotide construct
10/17/2012EP2511257A2 Alpha ketoamide compounds as cysteine protease inhibitors
10/17/2012EP2510949A1 Therapeutic agent for fibromyalgia
10/17/2012EP2510948A1 T cell activation inhibitor, pharmaceutical composition containing same, and screening method for t cell activation inhibiting substance
10/17/2012EP2510946A1 Conjugates of synthetic tlr agonists and uses therefor
10/17/2012EP2510944A1 Treatment of bacterial infections
10/17/2012EP2510940A1 Use of cyr61 protein for preparing medicine
10/17/2012EP2510939A1 Anti-connexin peptide mimetics and therapeutic uses thereof
10/17/2012EP2510938A1 Anti-connexin antisense compounds and use thereof for treating vascular disorders
10/17/2012EP2510937A1 Anti-connexin compounds and use thereof in combination with transplant or grafting procedures
10/17/2012EP2510931A1 Therapeutic medium for preventing and treating adenomas and prostatitis
10/17/2012EP2510929A1 Methods for treating bacterial infection
10/17/2012EP2510928A1 Aclidinium for use in improving the quality of sleep in respiratory patients
10/17/2012EP2510927A2 Use of dha, epa or dha-derived epa for treating a pathology associated with cellular oxidative damage
10/17/2012EP2510926A1 Use of saturated amines compounds in manufacture of medicaments for mobilizing peripheral blood hematopoietic stem cell
10/17/2012EP2510925A2 Small-Molecule modulators of TRP-P8 activity
10/17/2012EP2510924A1 Solid dispersions containing 20-o- -d-glucopyranosyl-20(s)-protopanaxadiol
10/17/2012EP2510922A1 Manufacturing process for tablet formulations comprising cefuroxime
10/17/2012EP2510811A2 Use of nutritional compositions for preventing disorders
10/17/2012EP2510788A2 Glyceryl ether compounds and their use
10/17/2012EP2510098A1 Methods and compositions for treating diseases, disorders or injury of the cns
10/17/2012EP2509991A2 Modulation of hsp47 expression
10/17/2012EP2509990A1 Novel phosph(on)ate- and sulf(on)ate-based phosphate modified nucleosides useful as substrates for polymerases and as antiviral agents
10/17/2012EP2509989A1 Sucrose octasulfates of zinc, the preparation of same and the pharmaceutical and cosmetic uses thereof
10/17/2012EP2509983A1 FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY
10/17/2012EP2509982A1 3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetylcholine receptor ligands
10/17/2012EP2509981A1 Inhibitors of diacylglycerol acyltransferase
10/17/2012EP2509980A1 Heterocyclic compounds containing an indole core
10/17/2012EP2509979A1 Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core
10/17/2012EP2509978A1 Azocyclic inhibitors of fatty acid amide hydrolase
10/17/2012EP2509975A1 Benzimidazole inhibitors of leukotriene production
10/17/2012EP2509974A1 Pyrazoles derivatives modulators of calcium release -activated calcium channel and methods for treatment of non- small cell lung cancer
10/17/2012EP2509967A1 Novel 24-membered cyclooctadepsipeptides from fungal strains and their use as anthelmintics or endoparasiticides
10/17/2012EP2509966A1 Amino oxazine derivatives
10/17/2012EP2509965A1 2-amino-5, 5-difluoro-5, 6-dihydro-4h-oxazines as bace 1 and/or bace 2 inhibitors
10/17/2012EP2509964A1 Heterocyclic sulfonamide derivatives
10/17/2012EP2509963A1 Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof.
10/17/2012EP2509961A1 Imidazolidinedione derivatives
10/17/2012EP2509960A1 Tgr5 agonists
10/17/2012EP2509957A1 Cysteine protease inhibitors
10/17/2012EP2509956A1 Cysteine protease inhibitors
10/17/2012EP2509955A1 Pyrazole derivatives as modulators of calcium release -activated calcium channel
10/17/2012EP2509954A1 4 -oxo- 1h -quinoline- 3 - carboxamides as modulators of atp -binding cassette transporters
10/17/2012EP2509953A2 Methods of facilitating neural cell survival using gdnf family ligand (gfl) mimetics or ret signaling pathway activators
10/17/2012EP2509952A1 Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds
10/17/2012EP2509950A1 5-amino- 4-hydroxypentoyl amides
10/17/2012EP2509949A2 Pyridinone hydroxycyclopentyl carboxamides: hiv integrase inhibitors with therapeutic applications
10/17/2012EP2509947A1 Azabicyclo[3.1.0]hex-2-yl derivatives, method for preparing same, and pharmaceutical compositions containing same
10/17/2012EP2509946A1 Spiro indole - cyclopropane indolinones useful as ampk modulators
10/17/2012EP2509945A1 4- (azacycloalkyl) -benzene-1, 3 -diol derivatives as tyrosinase inhibitors and their synthesis and use thereof
10/17/2012EP2509943A1 2-methylene-19,26-nor-(20s)-l&-hydroxyvitamin d3
10/17/2012EP2509942A2 Bis-acylated hydroxylamine derivatives
10/17/2012EP2509941A2 N-acylated hydroxylamine derivatives and o-acylated hydroxylamine derivatives
10/17/2012EP2509940A2 Amyloid binding agents
10/17/2012EP2509939A2 Novel n-benzylamide substitued derivatives of 2-(acylamido)acetic acid and 2-(acy-lamido) propionic acids: potent neurological agents
10/17/2012EP2509938A1 Fty720 halogenated derivatives
10/17/2012EP2509644A2 Dextrin hydrogel for biomedical applications
10/17/2012EP2509634A2 Stable formulations for lyophilizing therapeutic particles
10/17/2012EP2509620A2 Nanoparticle carrier systems based on human serum albumin for photodynamic therapy
10/17/2012EP2509619A2 Treatment methods utilizing stem cell mobilizers and immunosuppressive agents
10/17/2012EP2509609A2 Improved methods and compositions for vein harvest and autografting
10/17/2012EP2509607A1 Glycosaminoglycan mixtures
10/17/2012EP2509606A1 Novel medical use
10/17/2012EP2509605A1 P2x7: inhibition of epithelial cancers and papillomas
10/17/2012EP2509604A1 Method for removing cytokines from blood with surface immobilized polysaccharides
10/17/2012EP2509603A1 Methods of improving cognitive functions
10/17/2012EP2509602A1 Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
10/17/2012EP2509601A1 Small pyrimidine derivatives and methods of use thereof
10/17/2012EP2509600A1 Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation
10/17/2012EP2509599A2 Method of treating pancreatic cancer
10/17/2012EP2509598A1 N-substituted deoxynojirimycin compounds for use in inhibiting osteoclastogenesis and/or osteoclast activation
10/17/2012EP2509597A1 Selective beta-glucuronidase inhibitors as a treatment for side effects of camptothecin antineoplastic agents
10/17/2012EP2509596A2 Compounds and methods of treating ocular disorders
10/17/2012EP2509595A1 Inhibitors of hemopoietic cell kinase (p59-hck) and their use in the treatment of influenza infection
1 ... 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 ... 7860